April 29, 2022 06:37 AM EDTUpdated 07:50 PM

‘Natural evolution’: Carisma’s scientific co-founder moves into the CSO post; Vas Narasimhan enlists Ronny Gal to help with Novartis revamp

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

When Michael Klichinsky was working with the famed Penn researchers Carl June and Saar Gill as a grad student, he didn’t picture a C-suite title …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Natural evolution’: Carisma’s scientific co-founder moves into the CSO post; Vas Narasimhan enlists Ronny Gal to help with Novartis revamp

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

‘Nat­ur­al evo­lu­tion’: Caris­ma’s sci­en­tif­ic co-founder moves in­to the CSO post; Vas Narasimhan en­lists Ron­ny Gal to help with No­var­tis re­vamp

Senior Editor

Editor

Senior Reporter

Sign up to read this article for free.

‘Natural evolution’: Carisma’s scientific co-founder moves into the CSO post; Vas Narasimhan enlists Ronny Gal to help with Novartis revamp